Status:
COMPLETED
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Breast Neoplasm
Eligibility:
All Genders
Brief Summary
This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).
Detailed Description
Patients selected by investigator according to clinical routine
Eligibility Criteria
Inclusion
- Patients with metastatic breast cancer
Exclusion
- History of hypersensitivity to Caelyx or its components
- Women who are pregnant or breast-feeding
- Patients with severe myelosuppression
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
167 Patients enrolled
Trial Details
Trial ID
NCT00736333
Start Date
November 1 2006
End Date
June 1 2010
Last Update
November 5 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.